The Response Study: A French registry on pregnancy in women with MS and related disorders and their children up to 6 years—Protocol,recruitment status,and baseline characteristics

Abstract

Background:

Counseling on pregnancy is still challenging, particularly regarding the use of disease-modifying treatments (DMTs). We are lacking long-term outcomes in children exposed to DMTs.

Objectives:

This study aimed to set up a French pregnancy registry for women with multiple sclerosis (MS) and related disorders nested within the Observatoire Français de la Sclérose en Plaques (OFSEP) cohort.

Methods:

Prospective, observational, multicentric, epidemiological study in France. Neurological visits are organized according to routine practice. Data are collected on the OFSEP minimal datasheet. Auto-questionnaires on pregnancy are completed by patients at Months 5–6 and 8 during pregnancy, and Months 3, 6, and 12 postpartum. A specific survey on analgesia is completed by anesthesiologists. Pediatric data are collected from the child’s health book, where visits on Day 8, Month 9, and 24 are mandatory. Parents complete neurodevelopmental questionnaires at Year 1, Years 2 and 6.

Results:

The RESPONSE study started in August 2019. On 7 April 2023, 515 women were included. Baseline demographics are presented.

Conclusions:

RESPONSE will provide rich information on the global management of pregnancy in France and prospective data on children until the age of 6 years, exposed or not to a DMT, including data on neurodevelopment that can be compared to the general population.

Study funding:

EDMUS and ARSEP Foundation, Biogen, Roche.

Keywords

Multiple sclerosis pregnancy children disease-modifying treatments registry

Get full access to this article

View all access options for this article.

References

Confavreux

Hutchinson

Hours

, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285–291.

Vukusic

Marignier

. Multiple sclerosis and pregnancy in the “treatment era.” Nat Rev Neurol 2015; 11: 280–289.

Krysko

Dobson

Alroughani

, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023; 22(4): 350–366.

Tomson

Battino

Bonizzoni

, et al.; EURAP Study Group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: A prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17(6): 530–538.

Christensen

Grønborg

Sørensen

, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013; 309: 1696–1703.

Bjørk

Zoega

Leinonen

, et al. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurol 2022; 79: 672–681.

Langer-Gould

Smith

Albers

, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology 2020; 94: e1939–e1949.

Saposnik

Andhavarapu

Fernández

, et al. Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Mult Scler Relat Disord 2022; 57: 103389.

European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on risk assessment of medicinal products on human reproduction and lactation: From data to labelling, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-risk-assessment-medicinal-products-human-reproduction-lactation-data-labelling_en.pdf (2008, accessed 28 August 2023).

10.

Alwan

Chambers

Armenti

, et al. The need for a disease-specific prospective pregnancy registry for multiple sclerosis (MS). Mult Scler Relat Disord 2015; 4(1): 6–17.

11.

Thiel

Ciplea

Gold

, et al. The German Multiple Sclerosis and Pregnancy Registry: Rationale, objective, design, and first results. Ther Adv Neurol Disord. Epub ahead of print 22 November 2021. DOI: 10.1177/17562864211054956.

12.

Amato

Portaccio

Ghezzi

, et al.; MS Study Group of the Italian Neurological Society. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 2010; 75: 1794–1802.

13.

Sadovnick

Carruthers

Houtchens

, et al. Canadian Multiple Sclerosis Pregnancy Study (CANPREG-MS): Rationale and methodology. Can J Neurol Sci 2020; 47(1): 109–114.

14.

Jokubaitis

Skibina

Alroughani

, et al. The MSBase pregnancy, neonatal outcomes, and women’s health registry. Ther Adv Neurol Disord. Epub ahead of print 12 April 2021. DOI: 10.1177/17562864211009104.

15.

Vukusic

Casey

Rollot

, et al. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. Mult Scler 2020; 26(1): 118–122.

16.

Haute Autorité de Santé. Suivi et orientation des femmes enceintes en fonction des situations à risque identifiées. Synthèse des recommandations professionnelles, https://www.has-sante.fr/upload/docs/application/pdf/suivi_des_femmes_enceintes_-_recommandations_23-04-2008.pdf (May 2016, accessed 28 August 2023).

17.

Ministère de la Santé et de la Prévention. Carnet de santé, https://sante.gouv.fr/IMG/pdf/carnet_de_sante-num-.pdf (accessed 28 August 2023).

18.

Duyme

Capron

. L’Inventaire du Développement de l’Enfant (IDE). Normes et Validation Françaises du Child Development Inventory (CDI). Devenir 2010; 22: 13–26.

19.

Fenson

Dale

Reznick

, et al. MacArthur communicative development inventories: User’s guide and technical manual. San Diego, CA: Singular Publishing Group, 1993.

20.

Kern

Langue

Zesiger

, et al. Adaptations françaises des versions courtes des inventaires du développement communicatif de MacArthur-Bates. ANAE 2010; 107–108: 217–228.

21.

Chlebowski

Robins

Barton

, et al. Large-scale use of the modified checklist for autism in low-risk toddlers. Pediatrics 2013; 131: e1121–e1127.

22.

Goodman

. The extended version of the Strengths and Difficulties Questionnaire as a guide to child psychiatric caseness and consequent burden. J Child Psychol Psychiatry 1999; 40(5): 791–799.

23.

Vandentorren

Bois

Pirus

, et al. Rationales, design and recruitment for the Elfe longitudinal study. BMC Pediatr 2009; 9: 58.

24.

Santé Publique France. Rapport de Surveillance de la Santé Périnatale en France. Données de surveillance, https://syngof.fr/wp-content/uploads/2022/09/2022_Rapport_Surveillance_Perinatale.pdf (September 2022, accessed 28 August 2023).

25.

Vukusic

Carra-Dalliere

Ciron

, et al. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Mult Scler 2023; 29: 11–36.

26.

Friend

Richman

Bloomgren

, et al. Evaluation of pregnancy outcomes from the Tysabri^® (natalizumab) pregnancy exposure registry: A global, observational, follow-up study. BMC Neurol 2016; 16: 150.

27.

Ebrahimi

Herbstritt

Gold

, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015; 21(2): 198–205.

28.

Portaccio

Annovazzi

Ghezzi

, et al.; Study Group of the Italian Neurological Society. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. Neurology 2018; 90: e823–e831.

29.

Haghikia

Langer-Gould

Rellensmann

, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014; 71: 891–895.

30.

Proschmann

Thomas

Thiel

, et al. Natalizumab during pregnancy and lactation. Mult Scler 2018; 24: 1627–1634.

31.

Triplett

Vijayan

Rajanayagam

, et al. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. Mult Scler Relat Disord 2020; 40: 101961.

32.

Vukusic

Durand-Dubief

Benoit

, et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult Scler 2015; 21: 953–955.

33.

Portaccio

Moiola

Martinelli

, et al.; Study Group of the Italian Neurological Society. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology 2018; 90: e832–e839.

34.

Kleerekooper

Van Kempen

ZLE

Leurs

, et al. Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurol Neuroimmunol Neuroinflamm 2017; 5: e424.

35.

Roche Medical information. Ocrelizumab and pregnancy and lactation, https://medically.roche.com/content/sciencehub/global/en/medinfo/ocrevus/ocrevus-and-pregnancy-and-lactation-in-women-with-multiple-scler.html (October 20, 2023, accessed January 2nd, 2024).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB